Literature DB >> 20448075

A conflict of responsibility: no patient left behind.

Bryan N Becker.   

Abstract

In its program END THE WAIT, the National Kidney Foundation (NKF) outlined four comprehensive strategies to achieve the goal that within 10 years, every individual on the US waiting list will receive a transplant within 1 year of listing. Lifetime immunosuppressive coverage is a critical piece of the foundation of this program. Events in 2009 that were dedicated toward achieving a lifetime immunosuppressive benefit were complicated by legislative challenges and a dynamic that placed oral medications in the ESRD bundling proposal in direct conflict with the potential for the lifetime immunosuppressive benefit. In line with its mission, the NKF could not sacrifice one kidney patient constituency for another. Successful patient-centered organizations stay consistent with their mission. The NKF had to weigh the risk of postponing a long-sought goal and its relationships with other organizations with standards of patient safety and equitable and efficient patient care. In a perfect world, we never have to make such choices. In the real world, we can use such choices to forge new ways and dialogue to achieve better health care for all patients affected by kidney disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20448075     DOI: 10.2215/CJN.02610310

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  2 in total

1.  Cost-related immunosuppressive medication nonadherence among kidney transplant recipients.

Authors:  Roger W Evans; William H Applegate; David M Briscoe; David J Cohen; Christopher C Rorick; Barbara T Murphy; Joren C Madsen
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-16       Impact factor: 8.237

Review 2.  Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States.

Authors:  Bekir Tanriover; Patricia W Stone; Sumit Mohan; David J Cohen; Robert S Gaston
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-04       Impact factor: 8.237

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.